Asian patients who elect to undergo augmentation rhinoplasty often present with concerns of a low dorsum and a short nose. Many implant types are available to address the concerns of these patients, including synthetic materials (eg, silicone and expanded polytetrafluoroethylene \[ePTFE; Gore-Tex, W. L. Gore and Associates, Inc, Flagstaff, AZ\]), autologous grafts (derived from cartilage, bone, fascia, and/or dermis), or xenografts.^[@SJV253C1]^ No implant material or technique is regarded as the standard in augmentation rhinoplasty so each surgical plan must be customized to the patient.

Both autologous grafts and synthetic implants can result in acceptable outcomes of rhinoplasty. In general, synthetic implants are associated with higher rates of complications, such as displacement and extrusion.^[@SJV253C2]^ Patients tend to prefer autologous cartilage and bone grafts because of the optimal biocompatibility and decreased risks of infection and extrusion with these grafts.^[@SJV253C3]^ However, autologous grafting can yield unfavorable outcomes such as inconsistent volume and uncontrollable shape of the graft, an unreliable absorption rate, and possible donor-site morbidity.^[@SJV253C3]^ In a meta-analysis, Peled et al^[@SJV253C4]^ determined that implantation of alloplastic materials in rhinoplasty was associated with an acceptable rate of complications. These authors advocated the placement of alloplastic implants when autogenous materials are unavailable or insufficient. However, specific guidelines have not been established for transplanting alloplastic materials.

Fat grafting was first described by Neüber^[@SJV253C5]^ in 1893 and continues to be a frequently performed procedure owing to the ease of fat harvest, the abundance of graft material available, and the lack of transplant rejection. However, fat survival and retention rates are unpredictable, and complications such as abscesses, cysts, nodulation, and neurovascular injury may occur.^[@SJV253C6]^ With years of extensive research and refinement of surgical techniques, structural fat grafting has become a reliable treatment strategy with acceptable clinical outcomes.^[@SJV253C7]^ Lin et al^[@SJV253C8]^ introduced the concept of microautologous fat transplantation (MAFT) in 2007. These authors subsequently demonstrated that MAFT yields reliable results in facial rejuvenation.^[@SJV253C9]-[@SJV253C13]^ In the present study, we performed MAFT with the so-called one-third maneuver in 198 Asian patients who underwent primary augmentation rhinoplasty.

METHODS {#s2}
=======

Review of Literature Addressing Fat Grafting to the Nose {#s2a}
--------------------------------------------------------

A search on PubMed was performed on August 25 2015, with the keywords *fat grafting* and *nose* to identify patients treated from January 2000 to August 2015 who underwent fat grafting to the nose. Details of each study were summarized and primary findings were compared with the results of the present study.

Patients and Study Design {#s2b}
-------------------------

A total of 198 patients (180 women, 18 men) who presented for MAFT to correct their nasal dorsum from January 2010 to December 2014 were evaluated in a retrospective study. Patients who had undergone previous rhinoplasty, nasal implantation, or filler injections or had sustained trauma to the nasal dorsum were excluded from the study. Asian patients with thick and extendable dorsal skin for whom a second touch-up MAFT session was indicated to achieve favorable results were considered the best candidates for this study, though not all patients fit this criteria. It was not necessary to obtain approval from an institutional review board because fat grafting is a long-established procedure and because the microinjection device (MAFT-Gun, Dermato Plastica Beauty Co, Ltd, Kaohsiung, Taiwan; Figure [1](#SJV253F1){ref-type="fig"}) applied in this study has received ISO 13485 certification and CE marking. In addition, the establishment at which the MAFT-Gun is manufactured has undergone registration and listing with the US Food and Drug Administration (FDA) and the Taiwan FDA. Patients provided informed written consent preoperatively for all surgical procedures and for anesthesia, intraoperative video recording, and photography. The study was conducted in accordance with the guidelines of the Declaration of Helsinki. Figure 1.The microautologous fat transplantation (MAFT)-Gun. This device can be adjusted to precisely deliver 6 fat-parcel sizes (0.017 mL, 0.011 mL, 0.0083 mL, 0.0067 mL, 0.0056 mL, and 0.00420 mL).

Surgical Procedures {#s2c}
-------------------

Videos 1, 2, and 3 demonstrate MAFT and may be viewed at [www.aestheticsurgeryjournal.com](www.aestheticsurgeryjournal.com). Preoperative markings were made with the patient seated. The recipient area for fat transfer was drawn in the shape of an I (width, 6-8 mm) from the nasal tip to a point approximately 15 mm above the intercanthal line (Figure [2](#SJV253F2){ref-type="fig"}) with a fan-shaped cephalic end. This pattern was divided into upper, middle, and lower zones (Figure [2](#SJV253F2){ref-type="fig"}). The total volume of fat to be injected was deposited as needed into these 3 zones. Figure 2.Computer-generated views of this 38-year-old woman depicting the one-third maneuver for MAFT. The recipient area is drawn as a 6- to 8-mm-wide I shape extending from the nasal tip to 15 mm above the intercanthal line. This marking is evenly divided into 3 zones: the upper third (green), the middle third (blue), and the lower third (orange). The point of insertion is indicated with an x. (A) Frontal view. (B) Oblique view.

All patients received total intravenous anesthesia before fat grafting. Appropriate local anesthesia was applied as needed at donor and recipient sites. Fat primarily was harvested from the lower abdomen. The donor site was infiltrated with a tumescent solution (10 mL of 2% lidocaine \[20 mg/mL\]:30 mL of Ringer\'s lactate solution:0.2 mL of epinephrine \[1:1000\]). Approximately 10-15 minutes after infiltration, fat was harvested from the donor site with a blunt-tip cannula (diameter, 2.5 or 3.0 mm; ≥1 holes sized 1 mm × 2 mm). The lipoaspirate volume was approximately equal to the volume of the tumescent solution to ensure that fat constituted a major proportion of the lipoaspirate. To minimize damage to the lipoaspirate, the plunger of a 10-mL syringe connected to a liposuction cannula was withdrawn to approximately 2-3 mL to maintain a negative pressure of 270--330 mm Hg.^[@SJV253C9]^

Lipoaspirates were processed and purified by centrifugation at 3000 rpm (approximately 1200 *g*) for 3 minutes as described by Coleman.^[@SJV253C7]^ This procedure minimized graft contamination due to environmental exposure and manual manipulation. Centrifugation also facilitated separation of the lipoaspirate into layers. The top layer contained oil from ruptured fat cells; the middle layer contained purified fat; and the bottom layer contained blood, cellular debris, and fluid.

The purified fat was carefully transferred into a 1-mL Luer-slip syringe by means of a transducer. The syringe containing purified fat was loaded into a MAFT-Gun (Figure [1](#SJV253F1){ref-type="fig"}) connected to an 18-gauge, blunt-tip cannula. The device was set by adjusting a dial to deliver fat parcels of 0.0067 mL (ie, 1/150 mL) to 0.0056 mL (ie, 1/180 mL) with each trigger deployment (Figure [1](#SJV253F1){ref-type="fig"}). A puncture incision was made on the nasal tip with a no. 11 scalpel blade (Figure [2](#SJV253F2){ref-type="fig"}). This insertion point was infiltrated with 0.3-0.5 mL of 2% lidocaine HCl with epinephrine (1:50,000). Fat then was transferred by depressing the trigger while withdrawing the MAFT-Gun. Fat was meticulously transplanted in 2-3 layers of the nasal dorsum from the deepest to the most superficial layers (ie, from the deep areolar plane to the vascular/fibromuscular plane to the subcutaneous areolar plane). During MAFT, downward traction was applied to successive zones of the nose with the surgeon\'s nondominant hand. First, traction was placed on the middle third of the nose while grafting the upper third. Next, traction was placed on the lower third of the nose (ie, the nasal tip) while grafting the middle third. Fat was transferred to the nasal tip last. The insertion wound was then closed with 1 suture (6-0, nonabsorbable).

Postoperative Care {#s2d}
------------------

Massage was avoided postoperatively. The recipient area was dressed with compressive garments and adhesive paper tape to alleviate swelling. Routine postoperative care, oral antibiotics, and nonsteroidal anti-inflammatory drugs were administered for 3 days or as needed. The suture placed at the insertion site was removed 2-3 days postoperatively, and the sutures placed at the donor site were removed at 1 week postoperatively. All patients received routine follow-up at an outpatient clinic at 1, 3, and 6 months postoperatively. Most patients were monitored beyond this duration. Photographs were taken at each visit for comparisons over time.

Assessment of Patient Satisfaction {#s2e}
----------------------------------

At the final postoperative visit (ie, ≥6 months postoperatively), the nursing staff asked patients to indicate their subjective satisfaction with regard to the height and length of their nose. Responses were anonymous and satisfaction was scored on a 5-point Likert scale (1, very dissatisfied; 2, dissatisfied; 3, neutral; 4, satisfied; and 5, very satisfied).

RESULTS {#s3}
=======

A search on PubMed returned 8 studies addressing fat grafting to the nose that we regarded as comparable to the present study. Specifically, these studies involved fat grafting (1) in the refinement of cleft nose;^[@SJV253C14]^ (2) as a complementary procedure during open rhinoplasty;^[@SJV253C15]^ (3) in the presence/absence of rhinoplasty;^[@SJV253C16]^ (4) as a means of restoring volume in reconstructive surgery;^[@SJV253C17]^ (5) to treat sequelae of rhinoplasty;^[@SJV253C18]^ (6) in terms of microfat injection to treat secondary nasal deformities;^[@SJV253C19]^ (7) to correct complications of rhinoplasty;^[@SJV253C20]^ and (8) as a potential cause of nasal-tip numbness after lipofilling.^[@SJV253C21]^ In Table [1](#SJV253TB1){ref-type="table"}, we summarize the key findings and the benefits and drawbacks of each of these studies. Table 1.Summary of Literature ReviewAuthors (Year)TitleApplication of Fat GraftingStudy DurationTotal No. of Patients and No. Who Underwent 1, 2, or 3 Sessions; (Mean No. of Sessions)No. of Men/No. of WomenMean Age, Years (Range)Mean Injection Volume, mL (Range)Mean Follow-up, Months (Range)Primary ResultsKey ContributionsComments by Authors of the Present StudyPresent studyMicroautologous Fat Transplantation for Primary Augmentation Rhinoplasty: Long-term Monitoring of 198 Asian PatientsPrimary augmentation rhinoplasty for aesthetic purposes4 years198 patients; 126 (1 session) 70 (2 sessions) 2 (3 sessions);\
(1.4)18/18045.5 (26-58)3.4 (2.0-5.5)19 (6-42)Overall satisfaction rate of 63.1%First article to describe a large series of patients who underwent fat grafting in aesthetic primary augmentation rhinoplasty with MAFTMAFT is appropriate for primary augmentation rhinoplasty for aesthetic purposesDuskova et al^[@SJV253C27]^ (2004)Augmentation by Autologous Adipose Tissue in Cleft Lip and Nose. Final Esthetic Touches in Clefts: Part IReconstruction in cleft lip and nose to supplement a hypertrophic scarred lip and nasal columellaNS5 patients; (1 session) 3 (2 sessions) 1 (3 sessions)\
(2)1/4NS (26-38)4.3 (3-6)22 (NS)All 5 patients have pleasing resultsDescribed augmentation of the upper lip and columella by fat grafting is minimally invasive and results in physiologic shapes for the upper lip, nasal columella, and nasolabial angleSmall study but with promising resultsCárdenas et al^[@SJV253C28]^ (2007)Refinement of Rhinoplasty with LipoinjectionAs an adjunct to open rhinoplasty2 years, 3 months78 patients 78 (1 session)\
(1)7/71NS (14-56)NS (1-3)15 (1-36)Results of 68 patients considered excellent, 9 good, 1 unsatisfactoryDetermined that fat grafting can be applied to refine open rhinoplastyConcludes that fat grafting is an adjunct procedure with open rhinoplastyMonreal^[@SJV253C29]^ (2011)Fat Grafting to the Nose: Personal Experience With 36 PatientsPrimary augmentation, treatment of deformities after rhinoplasty, and in conjunction with rhinoplasty3 years, 3 months36 patients 33 (1 session) 2 (2 sessions)\
(1.1)NSNSHarvested 3-12 mL for lipoimplantation; 6-12 mL when combined with rhinoplasty7 (NS-14)80% (good-high) patient satisfaction, especially for deformities after rhinoplastyIdentified nasal danger zones and emphasized the importance of utilizing an 18-gauge, blunt injection needleOnly 18 of 36 patients (50%) presented for aesthetic purposesClauser et al^[@SJV253C30]^ (2011)Structural Fat Grafting: Facial Volumetric Restoration in Complex Reconstructive SurgeryVolumetric restoration in complex reconstructive surgery4 years, 5 months23 patients NA\
(NA)NSNS3.4 NSNSGood results and improvements in facial morphology, function, shape, and volumeDemonstrated the importance of structural fat grafting in facial volumetric restoration in complex reconstructive surgeryOnly 23 of 57 fat grafting procedures were discussedBaptista et al^[@SJV253C31]^ (2013)Correction of Sequelae of Rhinoplasty by LipofillingTo treat rhinoplasty sequelae, saddle nose, and sequelae of lateral osteotomy sequelae4 years20 patients 18 (1 session) 2 (2 sessions)\
(1.1)NS53 (NS)2.1 (1-6)NS (18-24)18 patients satisfied to very satisfied, 2 required second rhinoplastyDetermined that lipofilling could be a simple and reliable alternative to correct imperfections following rhinoplastyCorrection of sequelae of rhinoplasty in 20 patientsErol^[@SJV253C32]^ (2014)Microfat Grafting in Nasal SurgeryAs microfat transplantation in patients with secondary nasal deformities (group 1 slight irregularities; group 2, marked irregularities; group 3, severe deformities)5 years313 patients 264 group 1 patients (1-3 sessions) 38 group 2 patients (3-6 sessions) 11 group 3 patients (6-16 sessions)\
(NA)27/28625.7 NS0.3-0.8 mL for minimal irregularities; 1-6 mL for major irregularitiesNS (12-60)Autologous microfat injection is safe and effective for correcting slight irregularities of the noseDemonstrated that microfat grafting is effective for correcting minor irregularities of the nasal skin and is appropriate for patients who cannot undergo revision rhinoplastyMultiple injections may be necessary for correction of nasal irregularitiesNguyen et al^[@SJV253C33]^ (2014)Autologous Fat Grafting and RhinoplastyFor correction of rhinoplasty sequelae6 years20 patients (1 session) 2 (2 sessions)\
(1.1)NS53 NS2.1 (1-6)NS (18-24)18/20 patients satisfied to very satisfiedEmphasized the importance of utilizing a 21-gauge, 0.8-mm injection cannula vs an 18-gauge, 1.2 mm cannulaRelatively small study size to address correcting the sequelae of rhinoplastyHuang^[@SJV253C34]^ (2015)Does Sensation Return to the Nasal Tip After Microfat Grafting?Evaluation of severity of numbness in the nasal tip after fat grafting4 years30 patients 30 (1 session)\
(1)0/3020 (20-45)NS (1-3)NS (0-3)Nasal tip sensation improved for 96.2% of patients at 12-week visitDetermined that nasal tip sensation will recover completely after fat graftingEmphasized sensory recovery after fat grafting on tip only[^2]

The mean age of the patients was 45.5 years (range, 26-58 years). The MAFT operating time, including the duration from harvesting to transplantation, lasted an average of 25 minutes (range, 18-30 minutes). The mean fat volume delivered per session was 3.4 mL (range, 2.0-5.5 mL). The estimated fat retention rate was ≤50% at postoperative 6 months. Patients were monitored for an average of 19 months (range, 6-42 months). No major complications (eg, infection, skin necrosis, nodulation, fibrosis, or asymmetry) were recorded. Of 198 patients, 126 patients (63.6%) underwent 1 MAFT session, 70 (35.4%) underwent 2 sessions, and 2 (1.0%) underwent 3 sessions. All patients rated their satisfaction at the final postoperative visit (Table [2](#SJV253TB2){ref-type="table"}). Patient satisfaction rates with 1, 2, or 3 MAFT sessions were 46.0% (58 of 126 patients), 92.9% (65 of 70 patients), and 100% (2 of 2 patients), respectively. Overall, 125 of 198 patients (63.1%) indicated that they were satisfied with the results of MAFT, with 52 (26.2%) stating that they were 'very satisfied' and 73 (36.9%) stating that they were 'satisfied.' In addition, most of the patients reported subjective improvements in skin texture postoperatively, including shrinkage of pores, improvements in wrinkles at the nasal root, a shiny and moisturized skin appearance, and longer maintenance of makeup. Four patients are presented in Figures [3](#SJV253F3){ref-type="fig"} and [4](#SJV253F4){ref-type="fig"} and [Supplementary Figures 1 and 2](http://asj.oxfordjournals.org/lookup/suppl/doi:10.1093/asj/sjv253/-/DC1). Table 2.Patient Satisfaction After Augmentation Rhinoplasty With 1, 2, or 3 MAFT SessionsNo. of PatientsVery Unsatisfied, No. of Patients (%)Unsatisfied, No. of Patients (%)Neutral, No. of Patients (%)Satisfied, No. of Patients (%)Very Satisfied, No. of Patients (%)1 session1260 (0)5 (4.0)63 (50.0)38 (30.1)20 (15.9)2 sessions700 (0)0 (0)5 (7.1)35 (50.0)30 (42.9)3 sessions20 (0)0 (0)0 (0)0 (0)2 (100)Total1980 (0)5 (2.5)68 (34.3)73 (36.9)52 (26.2)[^3] Figure 3.(A, C, E, G, I, K) This 28-year-old woman presented for augmentation rhinoplasty with fat grafting to increase the height of her nose. MAFT was performed to place a 3.5-mL fat graft (1.5, 1.0, and 1.0 mL in the upper, middle, and lower thirds of the nasal dorsum, respectively). (B, D, F, H, J, L) One year after a single MAFT session, the fullness and height of the nose were maintained. Figure 3.Continued. Figure 4.(A, C, E, G) This 32-year-old woman presented for augmentation of the height and length of her nose. She underwent 2 sessions of MAFT with the one-third maneuver with a 6-month period between sessions. A total of 3 mL of fat was grafted in the first session and 4.5 mL of fat was grafted in the second session. (B, D, F, H) Two years after the second MAFT session, the results are stable and effective and appear natural.

DISCUSSION {#s4}
==========

Many types of autologous grafts and synthetic implants are available for augmenting and recontouring the nasal dorsum.^[@SJV253C2]-[@SJV253C4]^ Silicone or ePTFE are common synthetic materials with which surgeons have demonstrated acceptable and consistent clinical results in certain patients.^[@SJV253C4]^ However, long-term outcomes of nasal implantation with synthetic materials have not been established. Complication rates for deviation, incompatibility, and skeletonization resulting from capsular contracture are unacceptably high with synthetic implants.^[@SJV253C2]^ Autologous grafts comprising cartilage, bone, dermis, and osseocartilaginous composites are preferable because of their superior biocompatibility and effectiveness.^[@SJV253C22]-[@SJV253C26]^ However, autologous grafts are associated with high rates of reabsorption and complications at the donor site, and few reports have addressed the long-term outcomes of implantation with these materials.^[@SJV253C27]-[@SJV253C33]^ No optimal strategy exists for augmentation rhinoplasty, and the choice of implant material and technique currently must be customized to the patient (Table [3](#SJV253TB3){ref-type="table"}). Table 3.Implantation With MAFT vs Other Materials in Primary Augmentation RhinoplastySynthetic Implant (Silicone/ePTFE)Autologous Cartilage, Bone, DermisMAFTAutologous tissueNoYesYesImmune rejection/inflammatory reactionPossible/likelyUnlikelyUnlikelyPostoperative swelling and painHighModerateMinimalInfection rateHighLowVery low (none in this series)Deviation after operationLikelyOccasionalUnlikelyCapsular contracturePossibleOccasionalNoneMarginal demarcationClearVisibleNot visibleImprovement of skin textureNoNot determinedYesLevel of increasing dorsal height/lengthProminent, unnatural appearanceProminent, natural appearanceMay require several sessionsProjection of nasal tipEasily achievable, potential skeletonizationEasily achievable, natural appearanceDifficult/unachievableDonor-site morbidityNoScarMinimal[^4]

Coleman^[@SJV253C7],[@SJV253C34]^ emphasized that structural fat grafting to regions with thin skin, such as the periorbital area, must involve delivery of minute fat parcels (ie, 0.033-0.020 mL). The nasal dorsum is characterized by relatively thin skin and limited space and is a challenging anatomic site for the insertion of fine fat parcels. However, implantation of larger fat parcels is more likely to yield dislodgement of the implant, nodulation, and skin irregularities. Studies that have addressed fat grafting in rhinoplasty generally involve lipoinjection in the nose, with most authors applying fat grafting for refinement of rhinoplasty or for nasal reconstruction (Table [1](#SJV253TB1){ref-type="table"}).^[@SJV253C14]-[@SJV253C21]^ We performed a literature review and identified 8 articles that address fat grafting to the nose. The results of these studies all further the field of nasal augmentation. However, to our knowledge, the present study is the first to apply fat grafting as a means to lengthen the nose and/or increase the dorsal height for aesthetic purposes.

In the present study, we applied our expertise with MAFT^[@SJV253C8]-[@SJV253C13]^ to primary augmentation rhinoplasty with the one-third maneuver. With the MAFT-Gun, we delivered minute parcels of fat (ie, 0.0067-0.0055 mL) in a layered and modular fashion to increase the dorsal height and length of the nose (Videos 1-3). For patients in this study who received \>1 year of follow-up, the results of MAFT were stable (Figures [3](#SJV253F3){ref-type="fig"} and [4](#SJV253F4){ref-type="fig"} and [Supplementary Figures 1 and 2](http://asj.oxfordjournals.org/lookup/suppl/doi:10.1093/asj/sjv253/-/DC1)). Moreover, patients noticed benefits at the skin surface, such as improved texture. Similar findings of apparent skin rejuvenation after fat grafting have been reported by Mojallal et al^[@SJV253C35]^ and Hsu et al^[@SJV253C36]^ A prospective study involving a longer monitoring period is needed to confirm these findings.

MAFT was applied in this study to deposit fat parcels into 3 zones of the nose. This one-third maneuver involved fat grafting subsections of the nose while applying traction to the adjacent subsection such that fat was transferred successively to the upper, middle, and lower thirds. This strategy, akin to bricklaying, extended the dorsal length of the nose while maintaining its structural integrity and preventing cephalic retraction of the lower third of the nose. Although fat retention rates were ≤50%, satisfaction rates were acceptable for patients who underwent 1 MAFT session and were excellent for patients who underwent 2 or 3 sessions. According to Wu,^[@SJV253C37]^ the Asian nose comprises 5 well-defined layers of soft tissue overlying an osseocartilaginous framework. From most to least superficial, these layers include the skin, the subcutaneous areolar plane, the vascular-fibromuscular layer, the deep areolar plane, and the perichondrium/periosteum. In accordance with this anatomic basis, MAFT involves fat placement in 2-3 layers from the deepest to the most superficial planes (Videos 1-3).

Although the incidence of severe complications (eg, blindness) from fat grafting or filler injection is low, it is essential for the surgeon to possess extensive knowledge of the soft-tissue and vascular anatomy of the nose.^[@SJV253C37]-[@SJV253C39]^ In general, the surgeon performing MAFT should have mastery of nasal anatomy, should avoid vigorous maneuvers, and should closely observe the patient for signs and symptoms of complications. During the course of this study, we occasionally observed transient white coloration of the dorsal skin due to overinjection of fat, which caused vascular compression but not occlusion. When the color change did not resolve spontaneously within 3-5 minutes, 0.3-0.5 mL of injected fat was extruded from the insertion site.

Three factors inherent to MAFT help prevent severe complications. First, MAFT involves delivery of minute per-parcel volumes of fat (0.0056-0.0067 mL). Second, fat was injected with a cannula (18 gauge, blunt tip, 1.2 mm in diameter) that was larger than the lumen of the vessels near the nasal dorsum and therefore precluded vascular injury. Although the cannula penetrated the vessels incidentally, the intravascular injection volume (0.0056--0.0067 mL) would not occlude the lumen. Third, the extrusive pressure of the fat parcels was very low (2-4 mm Hg). This safeguard was in place to prevent a spike in local pressure that could propel a fat parcel upstream to the ophthalmic artery where it could occlude the central retinal artery and cause visual disturbance or blindness.^[@SJV253C9],[@SJV253C37]-[@SJV253C39]^

The present study is associated with several limitations. Adequate projection of the nasal tip and sufficient length or height of the nasal dorsum were difficult to achieve with a single session of MAFT. However, this is also a limitation of synthetic implants and autologous cartilage grafts. The results of our subjective measure of patient satisfaction were favorable, but an objective validation of MAFT is lacking from this study. Future work should include 3-dimensional imaging of MAFT results over time to evaluate fat retention and survival.

CONCLUSIONS {#s5}
===========

Fat grafting cannot be applied universally to address the concerns of Asian patients who present for rhinoplasty. However, the results of this study support the utility of MAFT with the one-third maneuver to increase the height and length of the nose in primary augmentation rhinoplasty. Favorable outcomes were obtained for patients with thick, elastic skin who presented with a short, flat nose and underwent ≥2 MAFT sessions. Our results indicated that patients were satisfied with the long-term results of MAFT.
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